HER2 testing and correlation with efficacy of trastuzumab therapy.

Monica Fornier, Mauro Risio, Catherine Van Poznak, Andrew Seidman

Research output: Contribution to journalArticle

Abstract

The need for accurate detection of HER2 status is becoming more apparent, as therapeutic decisions are influenced by this information in both the adjuvant and advanced-stage setting. Since the US Food and Drug Administration approved trastuzumab (Herceptin) for the treatment of metastatic breast cancer, the urgency of accurately evaluating HER2 status of breast cancer specimens, in order to identify patients who might benefit from this therapy, has increased. A wide range of assay methods are available for determining HER2 status, but immunohistochemistry followed by fluorescence in situ hybridization (FISH) is the recommended approach for ambiguous cases. FISH is not as widely available and is more costly than immunohistochemistry, but economic modeling shows that it is the most effective (and cost-effective) option.

Original languageEnglish
Pages (from-to)1340-1348, 1351
JournalOncology
Volume16
Issue number10
Publication statusPublished - Oct 2002

Fingerprint

Fluorescence In Situ Hybridization
Immunohistochemistry
Breast Neoplasms
United States Food and Drug Administration
Therapeutics
Economics
Costs and Cost Analysis
Trastuzumab

ASJC Scopus subject areas

  • Oncology

Cite this

Fornier, M., Risio, M., Van Poznak, C., & Seidman, A. (2002). HER2 testing and correlation with efficacy of trastuzumab therapy. Oncology, 16(10), 1340-1348, 1351.

HER2 testing and correlation with efficacy of trastuzumab therapy. / Fornier, Monica; Risio, Mauro; Van Poznak, Catherine; Seidman, Andrew.

In: Oncology, Vol. 16, No. 10, 10.2002, p. 1340-1348, 1351.

Research output: Contribution to journalArticle

Fornier, M, Risio, M, Van Poznak, C & Seidman, A 2002, 'HER2 testing and correlation with efficacy of trastuzumab therapy.', Oncology, vol. 16, no. 10, pp. 1340-1348, 1351.
Fornier M, Risio M, Van Poznak C, Seidman A. HER2 testing and correlation with efficacy of trastuzumab therapy. Oncology. 2002 Oct;16(10):1340-1348, 1351.
Fornier, Monica ; Risio, Mauro ; Van Poznak, Catherine ; Seidman, Andrew. / HER2 testing and correlation with efficacy of trastuzumab therapy. In: Oncology. 2002 ; Vol. 16, No. 10. pp. 1340-1348, 1351.
@article{338dd338f911435e9e0bcf668a617171,
title = "HER2 testing and correlation with efficacy of trastuzumab therapy.",
abstract = "The need for accurate detection of HER2 status is becoming more apparent, as therapeutic decisions are influenced by this information in both the adjuvant and advanced-stage setting. Since the US Food and Drug Administration approved trastuzumab (Herceptin) for the treatment of metastatic breast cancer, the urgency of accurately evaluating HER2 status of breast cancer specimens, in order to identify patients who might benefit from this therapy, has increased. A wide range of assay methods are available for determining HER2 status, but immunohistochemistry followed by fluorescence in situ hybridization (FISH) is the recommended approach for ambiguous cases. FISH is not as widely available and is more costly than immunohistochemistry, but economic modeling shows that it is the most effective (and cost-effective) option.",
author = "Monica Fornier and Mauro Risio and {Van Poznak}, Catherine and Andrew Seidman",
year = "2002",
month = "10",
language = "English",
volume = "16",
pages = "1340--1348, 1351",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "10",

}

TY - JOUR

T1 - HER2 testing and correlation with efficacy of trastuzumab therapy.

AU - Fornier, Monica

AU - Risio, Mauro

AU - Van Poznak, Catherine

AU - Seidman, Andrew

PY - 2002/10

Y1 - 2002/10

N2 - The need for accurate detection of HER2 status is becoming more apparent, as therapeutic decisions are influenced by this information in both the adjuvant and advanced-stage setting. Since the US Food and Drug Administration approved trastuzumab (Herceptin) for the treatment of metastatic breast cancer, the urgency of accurately evaluating HER2 status of breast cancer specimens, in order to identify patients who might benefit from this therapy, has increased. A wide range of assay methods are available for determining HER2 status, but immunohistochemistry followed by fluorescence in situ hybridization (FISH) is the recommended approach for ambiguous cases. FISH is not as widely available and is more costly than immunohistochemistry, but economic modeling shows that it is the most effective (and cost-effective) option.

AB - The need for accurate detection of HER2 status is becoming more apparent, as therapeutic decisions are influenced by this information in both the adjuvant and advanced-stage setting. Since the US Food and Drug Administration approved trastuzumab (Herceptin) for the treatment of metastatic breast cancer, the urgency of accurately evaluating HER2 status of breast cancer specimens, in order to identify patients who might benefit from this therapy, has increased. A wide range of assay methods are available for determining HER2 status, but immunohistochemistry followed by fluorescence in situ hybridization (FISH) is the recommended approach for ambiguous cases. FISH is not as widely available and is more costly than immunohistochemistry, but economic modeling shows that it is the most effective (and cost-effective) option.

UR - http://www.scopus.com/inward/record.url?scp=0012890297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0012890297&partnerID=8YFLogxK

M3 - Article

C2 - 12435204

AN - SCOPUS:0012890297

VL - 16

SP - 1340-1348, 1351

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 10

ER -